Variable processing and cross-presentation of HIV by dendritic cells and macrophages shapes CTL immunodominance and immune escape.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science, c2005-

Cross-Priming/*immunology ; Dendritic Cells/*immunology ; HIV-1/*immunology ; Immune Evasion/*immunology ; Macrophages/*immunology ; T-Lymphocytes, Cytotoxic/*immunology; Epitopes, T-Lymphocyte/immunology ; HIV Infections/immunology ; Humans ; Immunodominant Epitopes/immunology ; Mass Spectrometry

Dendritic cells (DCs) and macrophages (Møs) internalize and process exogenous HIV-derived antigens for cross-presentation by MHC-I to cytotoxic CD8⁺ T cells (CTL). However, how degradation patterns of HIV antigens in the cross-presentation pathways affect immunodominance and immune escape is poorly defined. Here, we studied the processing and cross-presentation of dominant and subdominant HIV-1 Gag-derived epitopes and HLA-restricted mutants by monocyte-derived DCs and Møs. The cross-presentation of HIV proteins by both DCs and Møs led to higher CTL responses specific for immunodominant epitopes. The low CTL responses to subdominant epitopes were increased by pretreatment of target cells with peptidase inhibitors, suggestive of higher intracellular degradation of the corresponding peptides. Using DC and Mø cell extracts as a source of cytosolic, endosomal or lysosomal proteases to degrade long HIV peptides, we identified by mass spectrometry cell-specific and compartment-specific degradation patterns, which favored the production of peptides containing immunodominant epitopes in all compartments. The intracellular stability of optimal HIV-1 epitopes prior to loading onto MHC was highly variable and sequence-dependent in all compartments, and followed CTL hierarchy with immunodominant epitopes presenting higher stability rates. Common HLA-associated mutations in a dominant epitope appearing during acute HIV infection modified the degradation patterns of long HIV peptides, reduced intracellular stability and epitope production in cross-presentation-competent cell compartments, showing that impaired epitope production in the cross-presentation pathway contributes to immune escape. These findings highlight the contribution of degradation patterns in the cross-presentation pathway to HIV immunodominance and provide the first demonstration of immune escape affecting epitope cross-presentation.

Nat Cell Biol. 1999 Oct;1(6):362-8. (PMID: 10559964)
J Exp Med. 2000 Jan 17;191(2):239-52. (PMID: 10637269)
Immunity. 2000 Jan;12(1):83-93. (PMID: 10661408)
Nat Med. 2001 Mar;7(3):344-9. (PMID: 11231634)
Biochem Biophys Res Commun. 2001 Jul 27;285(4):863-72. (PMID: 11467830)
AIDS. 2002 Jul 5;16(10):1319-29. (PMID: 12131208)
J Infect Dis. 2003 Jan 15;187(2):315-9. (PMID: 12552458)
Science. 2003 Feb 28;299(5611):1400-3. (PMID: 12610307)
Blood. 2003 May 1;101(9):3520-6. (PMID: 12511409)
J Immunol. 2003 Nov 15;171(10):5415-22. (PMID: 14607945)
Blood. 2003 Dec 15;102(13):4448-55. (PMID: 12933572)
J Virol. 2004 Feb;78(3):1324-32. (PMID: 14722287)
J Exp Med. 2004 Apr 5;199(7):905-15. (PMID: 15067030)
Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6092-7. (PMID: 15079077)
J Virol. 2004 Jul;78(13):7069-78. (PMID: 15194783)
J Infect Dis. 2004 Aug 15;190(4):713-21. (PMID: 15272399)
Nat Rev Immunol. 2004 Aug;4(8):630-40. (PMID: 15286729)
Immunity. 2004 Aug;21(2):155-65. (PMID: 15308097)
J Exp Med. 1996 Apr 1;183(4):1545-52. (PMID: 8666912)
AIDS Res Hum Retroviruses. 1996 Dec 10;12(18):1691-8. (PMID: 8959245)
Nat Med. 1997 Feb;3(2):205-11. (PMID: 9018240)
J Immunol. 1997 Oct 15;159(8):3707-16. (PMID: 9378956)
J Immunol. 1997 Dec 15;159(12):5769-72. (PMID: 9550370)
J Immunol. 1998 Jul 1;161(1):112-21. (PMID: 9647214)
Science. 1999 Feb 12;283(5404):978-81. (PMID: 9974389)
Science. 2005 Mar 11;307(5715):1630-4. (PMID: 15761154)
J Virol. 2005 Aug;79(16):10218-25. (PMID: 16051815)
J Virol. 2005 Nov;79(21):13239-49. (PMID: 16227247)
J Immunol. 2005 Nov 1;175(9):5940-9. (PMID: 16237087)
J Immunol. 2006 Mar 1;176(5):2697-701. (PMID: 16493024)
J Immunol. 2006 Apr 1;176(7):4094-101. (PMID: 16547245)
Cell. 2006 Jul 14;126(1):205-18. (PMID: 16839887)
Immunity. 2006 Oct;25(4):533-43. (PMID: 17046682)
Eur J Immunol. 2007 Jul;37(7):1752-63. (PMID: 17534864)
J Virol. 2007 Nov;81(22):12608-18. (PMID: 17728232)
Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6730-5. (PMID: 19346487)
Nat Immunol. 2009 Jun;10(6):636-46. (PMID: 19412183)
J Immunol. 2009 Jun 1;182(11):7131-45. (PMID: 19454710)
J Infect Dis. 2009 Jul 15;200(2):236-43. (PMID: 19505257)
Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17463-8. (PMID: 19805168)
Eur J Immunol. 2009 Nov;39(11):2955-65. (PMID: 19637232)
J Immunol. 2010 Sep 15;185(6):3426-35. (PMID: 20729332)
J Immunol. 2011 Jan 1;186(1):479-88. (PMID: 21115730)
J Virol. 2011 Feb;85(4):1541-53. (PMID: 21106750)
Immunity. 2011 Jan 28;34(1):85-95. (PMID: 21194983)
Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2384-9. (PMID: 21262813)
Proteomics. 2011 Mar;11(5):854-64. (PMID: 21280226)
J Virol. 2011 May;85(10):5232-6. (PMID: 21367907)
PLoS Pathog. 2011 May;7(5):e1001341. (PMID: 21589893)
J Clin Invest. 2011 Jun;121(6):2480-92. (PMID: 21555856)
Immunity. 2011 Aug 26;35(2):260-72. (PMID: 21782478)
J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):248-52. (PMID: 21709567)
J Immunol. 2012 Jun 15;188(12):5924-34. (PMID: 22586036)
PLoS One. 2012;7(8):e42579. (PMID: 22880042)
Cell Host Microbe. 2012 Oct 18;12(4):396-407. (PMID: 23084910)
PLoS Pathog. 2012;8(11):e1003042. (PMID: 23209413)
J Clin Invest. 2013 Jan;123(1):380-93. (PMID: 23221345)
Immunol Rev. 2013 Jul;254(1):295-304. (PMID: 23772627)
Eur J Immunol. 2013 Jun;43(6):1470-83. (PMID: 23526630)
BMC Cell Biol. 2013;14:35. (PMID: 23937268)
J Immunol. 2014 Apr 15;192(8):3496-506. (PMID: 24616479)
PLoS Pathog. 2014 Apr;10(4):e1004069. (PMID: 24743648)
Viruses. 2014 Aug;6(8):3271-92. (PMID: 25196483)
J Immunol. 2014 Nov 1;193(9):4322-34. (PMID: 25230751)
J Virol. 2014 Nov;88(22):12937-48. (PMID: 25165115)
J Clin Invest. 2007 Nov;117(11):3563-75. (PMID: 17975674)
Microbes Infect. 2008 May;10(6):689-98. (PMID: 18462973)
Immunity. 2008 Jun;28(6):787-98. (PMID: 18549799)
Blood. 2008 Dec 1;112(12):4712-22. (PMID: 18682599)
J Virol. 2009 Mar;83(6):2743-55. (PMID: 19116253)
Nat Protoc. 2009;4(4):461-9. (PMID: 19282851)
Nature. 2009 Apr 2;458(7238):641-5. (PMID: 19242411)
PLoS Pathog. 2009 Apr;5(4):e1000365. (PMID: 19343217)
PLoS Med. 2006 Oct;3(10):e403. (PMID: 17076553)
Science. 2007 Jan 5;315(5808):107-11. (PMID: 17204652)

R01 AI084106 United States AI NIAID NIH HHS; R01 AI084753 United States AI NIAID NIH HHS; R01 AI112493 United States AI NIAID NIH HHS; R21 AI060502 United States AI NIAID NIH HHS

0 (Epitopes, T-Lymphocyte)
0 (Immunodominant Epitopes)

Date Created: 20150318 Date Completed: 20150731 Latest Revision: 20201217

20240829

PMC4364612

10.1371/journal.ppat.1004725

25781895